secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001437749-24-009590
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia FY2023 net loss $11.6M; CardiAMP HF trial misses primary endpoint but subgroup shows benefit
--------------------------------------------------------------------------------

- Revenue $0.5M (down from $1.4M); net loss $11.6M; cash $1.1M at year-end; financing provides runway into Q2 2024.
- CardiAMP HF trial missed primary endpoint; interim data: 37% RR reduction in heart death equivalents overall.
- In NTproBNP-elevated subgroup (59% of patients): 86.2% RR reduction in heart death equivalents (2.9% vs 21.1%).
- Confirmatory Phase III CardiAMP HF II trial approved by FDA with >90% power; Medicare reimbursement certified.
- Morph DNA steerable sheath family expects FDA approval Q3 2024; two additional biotherapeutic delivery partnerships anticipated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/0001437749-24-009590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/bcda20240326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer